Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 552

RESPONSE to Motion re #473 MOTION for Summary Judgment That Claim 10 of the '933 Patent is Invalid on the Ground of Failure to Comply with Claim Differentiation Under Section 112, Paragraph 4 filed by Amgen Inc.. (Rich, Patricia)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 552

Case 1:05-cv-12237-WGY

Document 552

Filed 06/27/2007

Page 1 of 4

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

AMGEN INC.,

) ) Plaintiff, ) ) Civil Action No.: 05-12237 WGY v. ) ) ) F. HOFFMANN-LA ROCHE ) LTD., a Swiss Company, ROCHE ) DIAGNOSTICS GmbH, a German ) Company and HOFFMANN-LA ROCHE ) INC., a New Jersey Corporation, ) ) Defendants. ) __________________________________________)

AMGEN INC.'S RESPONSE TO ROCHE'S STATEMENT OF MATERIAL FACTS IN SUPPORT OF DEFENDANTS' MOTION FOR SUMMARY JUDGMENT THAT CLAIM 10 OF THE `933 PATENT IS INVALID FOR FAILURE TO COMPLY WITH CLAIM DIFFERENTIATION UNDER § 112, ¶ 4

1152863_1.DOC

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 552

Filed 06/27/2007

Page 2 of 4

Pursuant to LR, D. MASS. 56.1, plaintiff Amgen Inc. ("Amgen") hereby responds to defendants F. Hoffman-La Roche Ltd, Roche Diagnostics GmbH, and Hoffman-La Roche, Inc.'s ("Roche") Statement of Material Facts Supporting Motion for Summary Judgment under Local Rule 56.1 ("Roche's Facts"). 1. Amgen does not contest the statement of fact contained in Roche's Facts

paragraph 1, except to correct a typographical error noted in a 3/24/98 PTO Certificate of Correction, in the language of Claim 9 of the `933 patent, which properly reads: "A pharmaceutical composition comprising an effective amount of a glycoprotein product effective for erythropoietin therapy according to claim 1, 2, 3, 4, 5 or 6 and a pharmaceutically acceptable diluent, adjuvant or carrier." 2. paragraph 2. 3. Amgen does not contest the statement of fact contained in Roche's Facts Amgen does not contest the statement of fact contained in Roche's Facts

paragraph 3, except to correct a typographical error in the language of Claim 10 of the `933 patent, which properly reads: "A method for providing erythropoietin therapy to a mammal comprising administering an effective amount of a pharmaceutical composition of claim 9."

1

Case 1:05-cv-12237-WGY

Document 552

Filed 06/27/2007

Page 3 of 4

Dated: June 27, 2007

Respectfully submitted, AMGEN INC., By its attorneys, /s/ Patricia R. Rich D. DENNIS ALLEGRETTI (BBO#545511) MICHAEL R. GOTTFRIED (BBO# 542156) PATRICIA R. RICH (BBO# 640578) DUANE MORRIS LLP 470 Atlantic Avenue, Suite 500 Boston, MA 02210 Telephone: [phone] Facsimile: [phone] LLOYD R. DAY, JR. (pro hac vice) DAY CASEBEER, MADRID & BATCHELDER LLP 20300 Stevens Creek Boulevard, Suite 400 Cupertino, CA 95014 Telephone: [phone] Facsimile: [phone] WILLIAM GAEDE III (pro hac vice) McDERMOTT WILL & EMERY 3150 Porter Drive Palo Alto, CA 94304 Telephone: [phone] Facsimile: [phone] KEVIN M. FLOWERS (pro hac vice) MARSHALL, GERSTEIN & BORUN LLP 233 South Wacker Drive 6300 Sears Tower Chicago, IL 60606 Telephone: [phone] Facsimile: [phone]

Of Counsel: STUART L. WATT WENDY A. WHITEFORD MONIQUE L. CORDRAY DARRELL G. DOTSON KIMBERLIN L. MORLEY ERICA S. OLSON AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1789 [phone]

2

Case 1:05-cv-12237-WGY

Document 552

Filed 06/27/2007

Page 4 of 4

CERTIFICATE OF SERVICE I hereby certify that this document, filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of electronic filing and paper copies will be sent to those indicated as non-registered participants.

/s/ Patricia R. Rich Patricia R. Rich

3